CSL Completes Acquisition of Aventis Behring to create ZLB Behring

CSL Completes Acquisition of Aventis Behring to create ZLB Behring Melbourne, Australia, (April 1, 2004): CSL Limited today announced the completion on March 31, 2004 of its acquisition of global plasma therapeutics business, Aventis Behring from Aventis SA. CSL will combine Aventis Behring with ZLB Bioplasma to create a new business, ZLB Behring. With ZLB Behring and CSL Bioplasma, CSL is now positioned as a world leader in plasma therapeutics. CSL Managing Director, Dr Brian McNamee said "Today´s plasma products industry demands a broad portfolio of quality products, an innovative R&D